Stockscreener 앱 받기
1.61
2.42%
-0.04
시간 외 거래:
1.61
전일 마감가:
$1.65
열려 있는:
$1.65
하루 거래량:
2.05M
Relative Volume:
0.96
시가총액:
$716.38M
수익:
$69.64M
순이익/손실:
$-26.09M
주가수익비율:
-22.52
EPS:
-0.0715
순현금흐름:
$-38.80M
1주 성능:
-8.00%
1개월 성능:
-19.50%
6개월 성능:
-5.85%
1년 성능:
+11.81%
1일 변동 폭
$1.59
$1.655
1주일 범위
$1.59
$1.78
52주 변동 폭
$1.10
$2.68
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.61 | 716.38M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Oct 2026 $LXRX - MarketBeat
Lexicon Pharmaceuticals stock faces a Q2 loss as trials advance - AD HOC NEWS
Lexicon Pharmaceuticals, Inc.Common Stock (Nasdaq:LXRX) Stock Quote - FinancialContent
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga
Fair value rises to USD 4.55 for Lexicon Pharmaceuticals stock - AD HOC NEWS
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress - Yahoo Finance
Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00 - AD HOC NEWS
Lexicon Pharmaceuticals upgraded to Buy with ke... - Pluang
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More - Seeking Alpha
Analyst Bullish on Lexicon Pharmaceuticals' Prospects - Intellectia AI
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - Yahoo Finance
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - The Motley Fool
Cantor Fitzgerald Initiates Overweight on Lexicon Pharmaceuticals (LXRX) Ahead of Phase 3 Inpefa Data - GuruFocus
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy - Seeking Alpha
Why is Lexicon Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Investing.com
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
LXRX Initiated Coverage by Cantor Fitzgerald -- Rating Set at Ov - GuruFocus
Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target - TradingView
Lexicon Pharmaceuticals (NasdaqCM:LXRX) Stock Forecast & Analyst Predictions - Simply Wall Street
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating - Yahoo Finance
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Yahoo Finance
Lexicon Pharmaceuticals stock trades near its yearly low - AD HOC NEWS
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data - finance.yahoo.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens - Investing.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com UK
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - webull.com
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - simplywall.st
Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us
Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Three New York investor conferences will hear from Lexicon - Stock Titan
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - finance.yahoo.com
Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance
Sotagliflozin Linked to Fewer Heart-Failure Events in Patients With BP as Low as 100 - Stock Titan
Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexicon (LXRX) Results at a Glance: EPS Misses Its Estimate in the Reported Period; Post-Earnings: The Market Price Advances 0.87% at the CloseNegative Surprise Momentum - vinanet.vn
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus
Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - Yahoo Finance
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 - finance.yahoo.com
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
렉시콘 파마슈티컬스 주식 (LXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
6.05%
자본화:
|
볼륨(24시간):